Announces First USA Orders for Travelan(R)
Immuron has received its first US orders for Travelan(R) from the largest US travel medicine chain with over 240 clinics providing travel medicine services nationwide. Immuron CEO Dr Leearne Hinch said "Launching Travelan(R) in the USA is an important commercial milestone for the company, as we focus on growing Travelan revenues globally. The USA represents a significant market opportunity, and we are delighted by this initial success and the level of support and enthusiasm shown by travel clinics for Travelan(R)." Travelan is now available for sale in Australia, Canada and the USA, and is undergoing regulatory approval in China.
Travelan(R) is marketed as a dietary supplement in the US, and can be sold through pharmacists, drug stores and general stores. Immuron has implemented a direct sales model through niche retail and online channels to take advantage of the higher product margins realisable. The volume of initial US orders from travel clinics was higher than anticipated, and orders are expected to build with the potential for significant revenue as the US roll-out gains momentum. Travel clinics are an important channel for selling Travelan, as clinician recommendation of the product to people travelling to high risk destinations helps build brand awareness and consumer acceptance.
The company is also engaging with potential (nonexclusive) distribution partners for the large volume pharmacist and drug store channels to fully exploit the commercial potential of the US market.
To drive the US launch, Immuron appointed Mr Travis Robins as Director of US Sales. Travis is responsible for managing sales of Immuron's products in the USA, engaging with distributors and wholesalers, and providing technical product support to US customers. Travis is an accomplished sales executive with over 10 years' experience in sales and marketing across medical devices, biotechnology and specialty pharmaceuticals.
About Immuron Limited
Immuron Limited (ASX:IMC) (OTCMKTS:IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan(R) for the prevention of travellers' diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company's other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.
For more information visit: Immuron Website